Medical News

SHERIDAN, WYOMING – November 9, 2024 – Enhancing EUV Lithography Materials Production in Japan and South Korea
In a move set to revolutionize semiconductor manufacturing, FUJIFILM Corporation has announced the launch of its cutting-edge negative-tone resists and developer for EUV lithography. This technology is poised to become the cornerstone of advanced semiconductor manufacturing processes, paving the way for smaller, more powerful chips.    

Fujifilm has earned its stripes in the industry as the pioneer behind the world's first NTI process, a negative development process that has been instrumental in miniaturizing semiconductor circuits using ArF lithography. With the introduction of its negative-tone EUV resist and EUV developer, Fujifilm continues to push the boundaries of miniaturization, optimizing circuit pattern formation for the next generation of semiconductors.    

SHERIDAN, WYOMING – November 9, 2024 – FUJIFILM Holdings Corporation is pleased to announce that Kenji Sukeno, Chairman, Director & Board Chairman, has been awarded the prestigious Order of the Rising Sun, Gold and Silver Star. This distinguished honor, bestowed by the Japanese government, recognizes individuals who have made significant contributions to the nation and the public good.    
Mr. Sukeno's leadership has been instrumental in FUJIFILM's successful transformation. Despite the challenges posed by digitalization, he has guided the company to strategically invest in the healthcare sector, strengthening its foundation for future growth.    

SHERIDAN, WYOMING – November 9, 2024 – FUJIFILM Diosynth Biotechnologies, a leading Contract Development and Manufacturing Organization (CDMO) specializing in biologics, vaccines, advanced therapies, and oncolytic viruses, has announced the completion of the first phase of its expansion project at its Hillerød, Denmark site.  This achievement is a significant milestone in the company's plan to establish a global network of facilities dedicated to improving the manufacturing and delivery of life-saving medications.    

The first phase of the expansion project has resulted in the addition of six mammalian cell bioreactors, increasing the total capacity at the Hillerød site to an impressive 12 x 20,000 L bioreactors.  The next phase, backed by a substantial capital investment, will see the addition of 8 x 20,000 L bioreactors and two downstream processing streams.    

SHERIDAN, WYOMING – November 9, 2024 – Company Maintains Positive Outlook for the Remainder of the Fiscal Year
FUJIFILM Holdings Corporation today announced strong financial results for the first half of the fiscal year ending March 31, 2025. The company reported a 9.1% year-over-year increase in revenue, reaching JPY1,514.7 billion. This growth was primarily fueled by strong sales in the Electronics and Imaging businesses, along with favorable foreign exchange rates.    
Operating income also demonstrated a healthy increase of 8.0% year-over-year, reaching JPY135.6 billion. The company attributed this growth to the increase in revenue and the positive impact of exchange rates.    
Despite a slight decrease in net income attributable to FUJIFILM Holdings, which was down 2.9% year-over-year to JPY110.3 billion, the company remains optimistic about its future prospects.    

SHERIDAN, WYOMING – November 9, 2024 – Varian Medical Systems, a Siemens Healthineers company, is proud to showcase its innovative TrueBeam® radiotherapy system, a cutting-edge technology designed to revolutionize cancer treatment. TrueBeam integrates hardware, software, treatment regimens, and safety features to provide clinicians with the tools they need to deliver precise and effective radiation therapy.    

"Advances in radiation therapy are accelerating, creating new options for treatment and new sources of optimism in the fight against cancer," says Varian Medical Systems.    

TrueBeam's comprehensive capabilities enable clinicians to focus on patients and treatments rather than systems and technologies. The system's integrated imaging system allows for improved soft tissue target visualization and faster cone-beam CT (CBCT) acquisitions, facilitating breath-hold treatments.

SHERIDAN, WYOMING – November 9, 2024 – SHERIDAN, WYOMING – November 9, 2024 – When it comes to contact lens wear, open communication between eye care providers and patients is essential for achieving lasting satisfaction and optimal eye health. Alcon, a global leader in eye care, recognizes the importance of this relationship and emphasizes the value of in-depth discussions to address patient needs and concerns.

Understanding Patient Priorities

Eye care professionals (ECPs) need to understand what patients look for most in their contact lenses. Comfort is often a top priority, and patients need a safe space to discuss any discomfort they experience with their current lenses.

Research indicates that a significant percentage of patients hesitate to discuss comfort issues with their ECPs. Some patients may feel embarrassed or believe that discomfort is a normal part of wearing contact lenses.

SHERIDAN, WYOMING – November 9, 2024 – In a significant advancement for healthcare diagnostics, bioMérieux, a world leader in in vitro diagnostics, announces the launch of VIDAS® VITAMIN B12 TOTAL, a groundbreaking automated test designed to revolutionize the detection and management of vitamin B12 deficiency. This innovative test, which received CE marking, offers a rapid and efficient method for measuring vitamin B12 concentration in human serum or plasma, providing healthcare professionals with a critical tool for accurate diagnosis and timely treatment.

SHERIDAN, WYOMING – November 9, 2024 – SHERIDAN, WYOMING – November 9, 2024 – Alcon, a global leader in eye care dedicated to helping people see brilliantly, presented its latest innovations and clinical data at the American Academy of Ophthalmology (AAO) 2024 annual meeting. The company showcased advancements in glaucoma therapy, retina surgery, and dry eye treatment, demonstrating its commitment to improving patient outcomes and streamlining surgical workflows.

Voyager™ DSLT: Revolutionizing Glaucoma Treatment

Alcon's latest innovation for glaucoma therapy, the Voyager™ Direct Selective Laser Trabeculoplasty (DSLT) device, was a highlight of the event. This groundbreaking technology offers a first-line treatment option for glaucoma patients, eliminating the need for a gonio lens or manual aiming required for traditional Selective Laser Trabeculoplasty (SLT).

SHERIDAN, WYOMING – November 8, 2024 – Sanofi, a leading global biopharmaceutical company, has announced outstanding results for the third quarter of 2024, showcasing robust financial performance and significant progress in its innovative product pipeline.  The company's dedication to providing healthcare solutions for patients worldwide is reflected in its impressive double-digit sales growth and groundbreaking achievements in research and development.

Sanofi's Q3 2024 sales surged by 15.7% at constant exchange rates (CER), reaching €13,438 million. Business earnings per share (EPS) also saw a significant increase, rising by 12.2% on a reported basis and 17.6% at CER to reach €2.86. This strong performance was fueled by better-than-expected vaccine sales, particularly for influenza and Beyfortus (RSV), and the continued strong growth of Dupixent, the company's leading immunology drug.

Dupixent Continues its Impressive Growth Trajectory

SHERIDAN, WYOMING – November 8, 2024 – Sanofi, a global biopharmaceutical company, is taking a bold stance in the fight against cancer by launching a comprehensive program designed to support employees impacted by the disease. Recognizing the profound impact cancer can have on individuals and their families, Sanofi's "Cancer & Work: Acting Together" initiative provides a 360° approach to addressing the financial, emotional, social, and professional needs of its colleagues.

"We're creating an environment where everyone is supported to bring their best self to work," says a Sanofi spokesperson. This commitment is evidenced by Sanofi's participation in Publicis' #WorkingWithCancer global pledge, a public declaration to combat cancer and its associated stigmas in the workplace.